Shuttle Pharmaceuticals Holdings, Inc. Common Stock SHPH

$4.00 +11.42% at last close
Market Cap$2.10 million
P/E Ratio400.00
Div Yield—
Volume48.9K
52-Week Range $2.58$55.90

Key Stats

Today's Range
$3.50 – $4.09
50-Day Range
$2.58 – $4.80
52-Week Range
$2.58 – $55.90
Volume
49K shs
Average Volume
51K shs
Market Cap
$2.10 million
P/E Ratio
400.00
Dividend Yield
—

Valuation

P/E Ratio
400.00
Price / Book
0.63
Price / Sales
-0.22

Short Interest

Short Interest
11.25%
Days to Cover
1.00

Financials (TTM)

Revenue
$-9,516,824
Net Income
$-10,827,907
Net Margin
113.78%
Return on Equity
-323.58%
Debt-to-Equity
—

About Shuttle Pharmaceuticals Holdings, Inc. Common Stock

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
2
Exchange
XNAS
Listed
2022-08-31

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.